NASDAQ$ADPT
Adaptive Biotechnologies Corporation · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Adaptive Biotechnologies reported a 41% increase in revenue for the fourth quarter of 2019, reaching $24.2 million, driven by growth in both sequencing and development revenue.
Adaptive Biotechnologies reported strong topline growth in commercial products and critical progress in advancing clinical product pipeline for Q4 2019. Total revenue reached $24.2 million, a 41% increase year-over-year. The company is focused on building commercial infrastructure and expanding R&D resources for immunoSEQ Dx and the Genentech alliance in 2020.
- Revenue of $24.2 million, representing a 41% increase compared to the fourth quarter of 2018.
- Clinical tests for clonoSEQ increased 66% compared to the fourth quarter 2018.
- Initiated two additional pharma partnerships with AbbVie and Genentech to measure MRD using the clonoSEQ assay.
- Delivered a data package to Genentech for the company’s first selected T-cell receptor candidate.
Headline financials
Revenue & EPS history
Adaptive Biotechnologies · Revenue · Quarterly
$24.2M
Revenue by segment
Adaptive Biotechnologies · $38M total across 2 segments · Q3 2023
- MRD Business$24.7M+23.5%65.0%
- Immune Medicine Business$13.3M-52.3%35.0%
Forward guidance
Management will provide the 2020 revenue outlook on the conference call scheduled to discuss the 2019 financial results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+1.3%
Avg return
Earnings day
+0.0%
Avg return
5 days after
-0.9%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+33.2%
Q1 2025
Best reaction
-22.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -1.9% | +22.6% | |
| Q4 2025 | -4.3% | -5.2% | -9.8% | |
| Q3 2025 | -4.8% | -6.8% | -5.2% | |
| Q1 2025 | +33.2% | +19.7% | +29.3% | |
| Q4 2024 | -3.2% | +6.8% | -6.7% | |
| Q3 2024 | +1.2% | +3.1% | +9.0% | |
| Q2 2024 | -5.5% | +1.3% | +3.3% | |
| Q1 2024 | -1.2% | +8.7% | +21.1% | |
| Q4 2023 | +9.4% | +6.4% | -10.5% | |
| Q3 2023 | -22.2% | -9.3% | +4.4% | |
| Q2 2023 | -15.5% | -18.8% | -17.5% | |
| Q1 2023 | -8.3% | -5.8% | +6.4% | |
| Q4 2022 | +15.4% | +9.3% | -3.3% | |
| Q3 2022 | +13.2% | -0.9% | +14.1% | |
| Q2 2022 | +19.3% | +22.8% | -8.4% | |
| Q1 2022 | -1.1% | -19.2% | -22.5% | |
| Q4 2021 | +5.3% | -8.0% | -15.3% | |
| Q3 2021 | +6.7% | +5.7% | -26.6% | |
| Q2 2021 | +4.8% | -2.4% | +9.8% | |
| Q1 2021 | +0.9% | -11.2% | -1.0% | |
| Q4 2020 | -2.6% | +2.0% | -32.8% | |
| Q3 2020 | +8.0% | +2.1% | +14.9% | |
| Q2 2020 | -3.8% | +2.8% | +0.2% | |
| Q1 2020 | -6.7% | -0.2% | +9.9% | |
| Q4 2019 | -5.6% | -10.7% | -15.4% | |
| Q3 2019 | -3.7% | +0.7% | +11.8% | |
| Q2 2019 | +3.5% | +9.7% | -5.4% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro